Long-term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients.
Mary MathiasMarina AbashidzeAby AbrahamMark J BelletruttiManuel D CarcaoHervé ChambostAnthony K C ChanLeonid DubeyJonathan DucoreThierry LambertNatalya KavardakovaSunil LohadeValentin TureaJohn K M WuAnna KlukowskaPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)
No FVIII inhibitors developed during long-term prophylaxis in the NuProtect-Extension study. Prophylaxis with simoctocog alfa was efficacious and well-tolerated, and is therefore an attractive long-term option for children with severe haemophilia A.